Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bosutinib, Atc L01ea04 (Obg) for the Period October 1St, 2024 - September 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Abiraterone (Except Potency 500 Mg), Atc L02bx03 (Obg) for the Period October 1St, 2024 - September 30Th, 2026

Open House Biologics Discount Agreements 2024-09 - Golimumab

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dapagliflozin + Metformin, Atc A10bd15 (Obo) for the Period October 1St, 2024 - September 30Th, 2026

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bimekizumab, Atc L04ac21 (Obo) for the Period October 1St, 2024 - September 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dapagliflozin, Atc A10bk01 (Obo) for the Period October 1St, 2024 - September 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Faricimab, Atc S01la09 (Obo) for the Period October 1St, 2024 - September 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Allergen Extract from Exclusively Timothy Grass Pollen (Excl. Sut), Atc V01aa02 F. D. Z. 01.10.24-30.09.26

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures